Practical Experience of Using Riamilovir in Treatment of Patients with Moderate COVID-19
https://doi.org/10.37489/0235-2990-2020-65-7-8-27-30
Abstract
The article evaluates the results of Riamilovir use in treatment of patients with a moderate form of the disease caused by a new strain of the SARS-CoV-2 virus. It was found that the average time required to complete resolution of symptoms during treatment with the drug was 6-7 days. The first negative result of PCR analysis for the SARS-CoV-2 virus was registered on the 10-11th day of therapy; two consecutive negative PCR results for the SARS-CoV-2 virus were registered in the majority of patients by day 14–19 of treatment in 63±4.28%. The body temperature of the majority of patients (75%) returned to normal by the 4th day of treatment. CT scan showed improvement in the lungs of patients: a repeated CT scan performed on average on day 19 from the start of therapy showed no lung damage or no progression in 10±3.0% of patients following therapy. The CT scan of the lungs performed in 1-2 months after the treatment showed that the number of patients with no lung damage increased to 27±4.44%. As a result of treatment, a decrease in the C-reactive protein index was observed in patients. The tolerability level of the drug was assessed as good: no adverse events or significant deviations in laboratory parameters were detected.
About the Authors
A. U. Sabitov
Ural State Medical University of the Ministry of Health of the Russian Federation
Russian Federation
Ekaterinburg
Russian Federation
Ekaterinburg
V. V. Belousov
Ural State Medical University of the Ministry of Health of the Russian Federation
Russian Federation
Ekaterinburg
Russian Federation
Ekaterinburg
A. S. Edin
Russian State Research Center - Burnasyan Federal Medical Biophysical Center of Federal Medical Biological Agency
Russian Federation
Moscow
Russian Federation
Moscow
E. V. Oleinichenko
Polyclinic No. 3 of the Administrative Department of the President of the Russian Federation
Russian Federation
Moscow
Russian Federation
Moscow
E. P. Gladunova
Samara State Medical University of the Ministry of Health of the Russian Federation
Russian Federation
Samara
Russian Federation
Samara
E. P. Tikhonova
Krasnoyarsk State Medical University named after Prof. V. F.VoinoWYasenetsky of the Ministry of Health of the Russian Federation
Russian Federation
Krasnoyarsk
Russian Federation
Krasnoyarsk
T. Yu. Kuzmina
Krasnoyarsk State Medical University named after Prof. V. F.VoinoWYasenetsky of the Ministry of Health of the Russian Federation
Russian Federation
Krasnoyarsk
Russian Federation
Krasnoyarsk
Yu. S. Kalinina
Krasnoyarsk State Medical University named after Prof. V. F.VoinoWYasenetsky of the Ministry of Health of the Russian Federation
Russian Federation
Krasnoyarsk
Russian Federation
Krasnoyarsk
P. V. Sorokin
«Azol pharma» LLC
Russian Federation
Novouralsk
Russian Federation
Novouralsk
References
1. Sologub T.V., Tokin I.I., Midikari A.S., Tsvetkov V.V. A comparative efficacy and safety of using antiviral drugs in therapy of patients with influenza. Infectious Diseases. 2017; 15 (4): 25–32. [in Russian] doi: 10.20953/1729-9225-2017-3-25-32
2. Kalyuzhin O.V. Ostrye respiratornye virusnye infekcii: sovremennye vyzovy, novyj vzglyad na mesto induktorov interferonov v profilaktike i terapii. Lechashchij Vrach 2013; 9: 1–6. [in Russian]
3. Pyrc K., Berkhout B., van der Hoek L. Identification of new human coronaviruses. Expert Review of Anti-infective Therapy 2007; 5 (2): 245–253. doi:10.1586/14787210.5.2.245
4. Shchelkanov M.Yu., Popova A. Yu., Dedkov V.G., Akimkin V.G., Maleyev V.V. History of investigation and current classification of coronaviruses (Nidovirales: Coronaviridae). Russian Journal of Infection and Immunity 2020; 10 (2): 221–246. [in Russian] doi: https://doi.org/10.15789/2220-7619-HOI-1412
5. Pitsiou G.G., Kioumis I.P. Severe acute respiratory syndrome (SARS). [Internet] BMJ Best Practices; 2020 [cited 2020 Aug 7]. Available from: https://bestpractice.bmj.com/topics/en-gb/904/
6. Distribution of confirmed cases of MERS-CoV by place of infection and month of onset, from March 2012 to 2 December 2019. 2019 Dec 6 [cited 2020 Aug 7]. In: European Centre for Disease Prevention and Control (ECDC) [Internet]. Available from:https://www.ecdc.europa.eu/en/publications-data/distribution-confirmed-cases-mers-cov-place-infectionand-month-onset-march-2012
7. WHO Director-General's opening remarks at the media briefing on COVID-19. 2020 Mar 11 [cited 2020 Aug 7]. In: World Health Organization [Internet]. Available from: https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020
8. COVID-19 Dashboard by the Center for Systems Science and Engineering at Johns Hopkins University [dashboard]. ArcGIS.Johns Hopkins University. August 7, 2020. Available at: https://www.arcgis.com/apps/opsdashboard/index.html#/bda7594740fd40299423467b48e9ecf6. Accessed August7, 2020.
9. Tikhonova, E. P., Kuz'mina, T. Y., Andronova, N. V., Tyushevskaya, O. A., Elistratova, T. A., Kuz'min A. E. Study of effectiveness of antiviral drugs (umifenovir, triazavirin) against acute respiratory viral infections. Kazan Medical Journal 2018; 99 (2): 215–223. [InRussian]. doi: 10.17816/KMJ2018-215
10. Kiselev O.I., Deyeva E.G., Melnicova T.I., Kozeletskaia K.N., Kiselev A.S., Rusinov V.L. et al. A new antiviral drug triazavirin: results of phase II clinical trial. Problems of Virology 2012; 57 (6): 9–12. [inRussian]
11. Verevshchikov V. K., Shemyakina E. K., Sabitov A. U., Batskalevich N. A. Modern Etiotropic Therapy of Influenza and ARVI in Adult Patients with Premorbid Pathology. Antibiotiki i Khimioter 2018; 63: 7–8. [in Russian]
12. Tokin I.I., Zubkova T.G., DrozdovaY.V., Lioznov D.A. Experience of etiotropic therapy of acute respiratory viral infection with domestic antiviral drug.Infectious Diseases 2019;17 (4): 13–17. [in Russian]. doi: 10.20953/1729-9225-2019-4-13-1
13. Kasianenko K.V., Lvov N.I., Maltsev O.V., Zhdanov K.V. Nucleoside analogues for the treatment of influenza: history and experience. Journal Infektologii 2019; 11: 3. [in Russian]
14. Tang W., Cao Z., Han M. et al. Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial. BMJ 2020; 369: m1849. doi:10.1136/bmj.m1849
15. Mitjà O., Corbacho-Monné M., Ubals M. et al. Hydroxychloroquine for Early Treatment of Adults with Mild Covid-19: A Randomized-Controlled Trial. ClinInfect Dis 2020; ciaa1009. doi:10.1093/cid/ciaa1009
16. Skipper C.P., Pastick K.A., Engen N.W. et al. Hydroxychloroquine in Nonhospitalized Adults With Early COVID-19: A Randomized Trial. Ann Intern Med 2020; M20–4207. doi:10.7326/M20-4207
17. Ye X.T., Luo Y.L., Xia S.C. et al. Clinical efficacy of lopinavir/ritonavir in the treatment of Coronavirus disease 2019. Eur Rev Med Pharmacol Sci 2020; 24 (6): 3390–3396. doi:10.26355/eurrev_202003_20706
18. Li Y., Xie Z., Lin W., Zhang F., Deng X., Li L. et al. Efficacy and safety of lopinavir/ritonavir or arbidol in adult patients with mild/moderate COVID-19: an exploratory randomized controlled trial. Cellpress. 2020. doi: 10.1016/j.medj.2020.04.001
19.
Review
For citations:
Sabitov A.U., Belousov V.V., Edin A.S., Oleinichenko E.V., Gladunova E.P., Tikhonova E.P., Kuzmina T.Yu., Kalinina Yu.S., Sorokin P.V. Practical Experience of Using Riamilovir in Treatment of Patients with Moderate COVID-19. Antibiot Khimioter = Antibiotics and Chemotherapy. 2020;65(7-8):27-30. (In Russ.) https://doi.org/10.37489/0235-2990-2020-65-7-8-27-30
Views:
9017
Email this article 